FDA has approved Cablivi, first therapy for the treatment of adult patients with a rare blood clotting disorder, acquired thrombotic thrombocytopenic purpura
The FDA ( U.S. Food and Drug Administration ) has approved Cablivi ( Caplacizumab-yhdp ) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive ...
read article